Deep Dive: Nutritional Deficiency Risks on GLP-1 Medications

You’re eating less. You know this — it’s the whole point. The appetite suppression is doing what it’s supposed to do. But here’s the question that doesn’t come up often enough: if you’re taking in 25-35% fewer calories than before, are you still getting everything your body needs?

The short answer, according to the largest studies we have, is probably not.

None of this is meant to scare you. These deficiencies are manageable — but only if you know they’re happening. And right now, most providers aren’t looking.

---

The Scope of the Problem

The Big Number

The largest dataset we have on nutritional deficiencies during GLP-1 therapy comes from a 2025 retrospective study of 461,382 adults newly prescribed GLP-1 receptor agonists between 2017 and 2021. The findings:[1]

One in five people. Within a year. And this was based on diagnosed deficiencies — meaning providers had to actually test for them. The real number is almost certainly higher.

What the Intake Data Shows

A 2025 cross-sectional study published in Frontiers in Nutrition looked at actual nutrient intake in 69 adults currently using GLP-1 medications. The results were striking:[2]

Nearly every participant was below the Dietary Reference Intake for vitamin D and potassium. Not “a little below” — vitamin D intake averaged 20% of the recommended amount.

The Narrative Review That Named It

In 2026, Urbina and colleagues published a narrative review synthesizing data across six studies encompassing 480,825 adults on GLP-1 therapy. Their conclusion was blunt: “Micronutrient deficiencies during GLP-1 therapy are a common consequence rather than a rare adverse effect.”[3]

That’s an important distinction. We’re not talking about an unlucky few. We’re talking about a predictable outcome of sustained caloric reduction that most clinical protocols aren’t accounting for.

---

The Nutrient-by-Nutrient Breakdown

Vitamin B12

Why it matters on GLP-1s: B12 is essential for nerve function, red blood cell production, and DNA synthesis. Deficiency can cause irreversible neurological damage if it goes on long enough — and the symptoms are easy to dismiss as “just tired from eating less.”

The data: Direct studies measuring B12 during GLP-1 therapy are still limited — but what exists is concerning. The only study to directly track serum B12 levels during semaglutide treatment found a significant decline from a median of 522 to 399 pg/mL over 12 months — roughly a 13% drop.[4] In the larger population data, vitamin B deficiency diagnoses reached 2.6% at 12 months — though that almost certainly underestimates reality, since it only captures cases where providers actually tested for it.[1]

The mechanisms are stacked against you:

1. Delayed gastric emptying — slows the transfer of B12 to the small intestine where absorption happens
2. Reduced stomach acid — B12 has to be cleaved from food proteins by stomach acid before it can bind to intrinsic factor for absorption
3. Reduced food intake — less dietary B12 coming in, especially from animal proteins
4. Potential effects on intrinsic factor — the gastric physiology changes from GLP-1s may affect intrinsic factor production

The metformin compounding effect: Many people on GLP-1s — especially those with Type 2 diabetes — are also taking metformin. Metformin independently impairs B12 absorption through a different mechanism (it interferes with calcium-dependent B12-intrinsic factor absorption in the ileum). The deficiency rate in metformin users alone is approximately 24%. Add GLP-1 therapy on top of that, and you’ve got two separate mechanisms both reducing B12 status simultaneously.[5]

Symptoms to recognize:

---

Iron

The landmark study: A 2025 pilot study by Melis and colleagues directly measured iron absorption before and after semaglutide treatment in 51 patients. This is the first study to objectively measure what GLP-1s do to iron absorption — not just intake, but actual absorption.[6]

The results: After 10 weeks on semaglutide, iron absorption dropped by a median 13% compared to pre-treatment levels. Nearly 18% of participants experienced a 30% or greater reduction. Only one participant in the entire study demonstrated an adequate iron absorption response after treatment.

From the larger population data: The Urbina review found that GLP-1 users had 26-30% lower ferritin levels (ferritin is your body’s iron storage marker) compared to people on SGLT2 inhibitors — a different class of diabetes medication. And 88.4% of GLP-1 users in the Frontiers study were below the DRI for iron.[2][3]

Why it happens:

Who’s most at risk: People who menstruate (higher iron needs due to monthly blood loss), people eating very low calorie levels, vegetarians and vegans on GLP-1s, and anyone with pre-existing iron deficiency.

---

Vitamin D — The Paradox

This one’s complicated, because weight loss and vitamin D have an unusual relationship.

The background: Vitamin D is fat-soluble and gets stored in adipose tissue. In people with obesity, vitamin D essentially gets diluted — sequestered in a larger volume of fat — which is why obesity is associated with a 3.4 times higher risk of vitamin D deficiency.[7]

The weight loss release effect: When you lose weight and fat cells shrink, they release stored vitamin D back into circulation. The effect is dose-dependent:[8]

So weight loss should help, right? In theory, yes. In practice, it’s not enough.

The reality: Despite this release effect, 13.6% of GLP-1 users had diagnosed vitamin D deficiency at 12 months — making it the single most common deficiency in the Elgebaly study. And 98.6% of GLP-1 users in the Frontiers study were below the dietary reference intake.[1][2]

Why the paradox resolves toward deficiency: The release from fat stores is real but finite. Meanwhile, dietary intake of vitamin D has collapsed — 98.6% below DRI — and reduced fat intake on GLP-1s impairs absorption of this fat-soluble vitamin. The release provides a temporary buffer, not a long-term solution.

---

Calcium and Bone Density

This is where the data gets genuinely important — and where the strongest argument for exercise during GLP-1 therapy comes from.

GLP-1 medications alone reduce bone mineral density. A 2024 randomized controlled trial by Hansen and colleagues found that semaglutide increased bone resorption markers (meaning more bone was being broken down) without increasing bone formation markers. BMD declined at both the lumbar spine and total hip.[9]

But exercise changes everything. The Lundgren JAMA 2024 study is one of the most clinically significant findings in this entire research area. In 195 adults with obesity, the combination of liraglutide plus exercise produced the following results:[10]

Read that combination row carefully. The group that combined GLP-1 medication with exercise lost the most weight — 16.88 kg — and completely preserved bone density. The GLP-1-only group lost less weight and still lost bone. Exercise didn’t just offset the bone loss. It eliminated it entirely while allowing even greater weight loss.

From my experience, this is the single data point I bring up most when people ask me about exercise and GLP-1s. It’s not about burning calories. It’s about protecting your skeleton while you lose weight. The argument for resistance training and weight-bearing exercise isn’t optional — it’s structural.

A tirzepatide note: Early real-world data suggests tirzepatide may carry a higher risk of osteoporosis or fragility fractures compared to other GLP-1 receptor agonists, though the evidence is still emerging from retrospective cohorts.[11]

Calcium absorption matters too: Calcium citrate is absorbed at roughly 45% efficiency regardless of stomach acid levels. Calcium carbonate — the cheaper, more common form — drops to about 4% absorption when stomach acid is reduced, which is directly relevant to GLP-1 users with altered gastric physiology. Your body can only absorb about 500-600 mg of calcium at a time, so it needs to be split across multiple doses.[12]

---

Other Micronutrients at Risk

The nutrients above get the most research attention, but they’re not the whole picture.

---

The Bariatric Surgery Comparison

Here’s a useful way to frame the monitoring gap: compare GLP-1 therapy to bariatric surgery.

Bariatric surgery causes actual malabsorption — the digestive tract is physically altered, bypassing portions of the small intestine where nutrients are absorbed. GLP-1 medications don’t do this. The gut anatomy stays intact. But the caloric reduction is still dramatic enough that the deficiency profiles overlap significantly.[13][14]

The critical difference isn’t the biology — it’s the infrastructure. Bariatric surgery patients get mandatory pre-operative nutritional assessments, standardized supplement protocols, and scheduled lab monitoring for the rest of their lives. GLP-1 patients get a prescription and a follow-up in three months.

---

What Monitoring Looks Like

Until formal guidelines are established, the following recommendations are drawn from the 2025 Joint Advisory, the Urbina narrative review, and adapted bariatric surgery protocols:[13][14]

Baseline Labs (Before or Soon After Starting)

Ongoing Schedule

• Repeat nutritional labs at 6 months, 12 months, then annually
• Check sooner if: Unexplained fatigue beyond what’s typical, numbness or tingling, unusual hair loss, poor wound healing, muscle weakness, losing weight faster than 1% of body weight per week

High-Risk Populations

Some people need closer monitoring from the start:

Body Composition Assessment

Weight alone doesn’t tell you what you’re losing. Two approaches exist:

---

The Bottom Line

Twenty-two percent of GLP-1 users develop a diagnosable nutritional deficiency within a year. Nearly everyone falls short on vitamin D, potassium, and magnesium intake. Iron absorption measurably drops. Bone density declines without exercise. And right now, the medical system has no standardized protocol for catching any of it.

That’s the bad news. Here’s the good news: every single one of these problems is solvable.

A daily multivitamin, targeted supplements where labs show gaps, calcium citrate instead of carbonate, B12 monitoring if you’re on metformin, and exercise to protect your bones — none of this is complicated. It just requires knowing to do it.

The gap isn’t in the science. The science is clear. The gap is in the clinical workflow — and until your provider’s standard protocol catches up to the research, you may need to be the one who brings this conversation to them. Print this page if it helps. Bring a list of the labs in the monitoring section. Ask the questions.

This is manageable. You just have to know it’s there.

---